Evidence map›Paper›PMID 36313638›Full record

ArticleFrontiers in oncology2022

A novel amino acid metabolism-related gene risk signature for predicting prognosis in clear cell renal cell carcinoma.

Jiaqi Su, Xi Tian, Zihao Zhang, Wenhao Xu, Aihetaimujiang Anwaier, Shiqi Ye, Shuxuan Zhu, Yue Wang, Guohai Shi, Yuanyuan Qu and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiaqi SuDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Xi TianDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Zihao ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Wenhao XuDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Aihetaimujiang AnwaierDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Shiqi YeDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Shuxuan ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Yue WangDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Guohai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, School of Life Sciences, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cancer is one of the most lethal cancers because of its atypical symptoms and metastatic potential. The metabolism of amino acids and their derivatives is essential for cancer cell survival and proliferation. Thus, the construction of the amino acid metabolism-related risk signature might enhance the accuracy of the prognostic model and shed light on the treatments of renal cancers. Methods: RNA expression and clinical data were downloaded from Santa Cruz (UCSC) Xena, GEO, and ArrayExpress databases. The "DESeq2" package identified the differentially expressed genes. Univariate COX analysis selected prognostic genes related to the metabolism of amino acids. Patients were divided into two clusters using the "ConsensusClusterPlus" package, and the CIBERSORT, ESTIMATE methods were explored to assess the immune infiltrations. The LASSO regression analysis constructed a risk model which was evaluated the prediction accuracy in two independent cohorts. The genomic alterations and drug sensitivity of 18-LASSO-genes were assessed. The differentially expressed genes between two clusters were used to perform functional enrichment analysis and weighted gene co-expression network analysis (WGCNA). Furthermore, external validation of Results: The amino acid metabolism-related genes had significant correlations with prognosis. The patients in Cluster A demonstrated better survival, lower Treg cell proportion, higher ESTIMATE scores, and higher cuproptosis-related gene expressions. Amino acid metabolism-related genes with prognostic values were used to construct a risk model and patients in the low risk group were associated with improved outcomes. The Area Under Curve of the risk model was 0.801, 0.777, and 0.767 at the first, second, and third year respectively. The external validation cohort confirmed the stable prognostic value of the risk model. WGCNA identified four gene modules correlated with immune cell infiltrations and cuproptosis. We found that Conclusion: Our study firstly constructed an 18 amino acid metabolism related signature to predict the prognosis in clear cell renal cell carcinoma. We also identified four potential gene modules potentially correlated with cuproptosis and identified

Indexed as

amino acid metabolismclear cell renal cell carcinomacuproptosisrisk signaturetransmembrane protein 72

Identifiers

PMID36313638
PMCPMC9614380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.